Wolf, Markus ; Bauder-Wüst, Ulrike ; Pipkorn, Rüdiger
Preview |
PDF, English
Download (66kB) | Terms of use |
Citation of documents: Please do not cite the URL that is displayed in your browser location input, instead use the DOI, URN or the persistent URL below, as we can guarantee their long-time accessibility.
Abstract
The majority of magnetic resonance contrast agents are restricted to the extracellular domains. For the development of novel, intracellular magnetic resonance contrast agents, we have designed Gd-DOTA derivatives comprising PreS2-TML peptide or ethylguanidinium as carrier moiety. Initial in vitro cell uptake studies with Jurkat cells revealed efficient contrast agent uptake for imaging purposes, in the range of 0.04 fmol/cell (PreS2-TML peptide) to 0.2 fmol/cell (ethylguanidinium) following 2 h incubations at 100 µM.
Document type: | Article |
---|---|
Date Deposited: | 23 Mar 2006 14:54 |
Date: | 2006 |
Faculties / Institutes: | Service facilities > German Cancer Research Center (DKFZ) |
DDC-classification: | 610 Medical sciences Medicine |
Controlled Keywords: | NMR-Bildgebung, Kontrastmittel |
Uncontrolled Keywords: | MRI , contrats agent, guanidinium , PreS2TML |